Equity
€2.7m from €4.8m in 2024
Equity fell by 45% in 1 year.
Anima Research
Lifetime
20 annual accounts with figures on one time axis, 32 filings since 1994Gross marginpeak €2.7m (2023)
-€1.3m▼ €3.2m
Resultlowest -€2.2m (2025)
-€2.2m▼ €2.7m
Equitypeak €4.8m (2024)
€2.7m▼ 44.8%
Debts
€1.6m▼ 35.4%
Staffpeak 7 FTE (2024)
6 FTE▼ 14.3%
Board8 names since 2021
4 directorsEB Pharma Developments and 3 others
Owners4 names in the annual accounts
20%BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM and 3 others
Documentsfilings and deeds
23-10-202684 days late
2025abbreviated format
Gross margin from €2.0m to -€1.3mLoss of €2.2mStaff from 7 FTE to 6 FTEAppointment: BV VAN HAVERMAET BEDRIJFSREVISOREN (statutory au… 12-05Appointment: Linde Buntinx BV (day-to-day manager) 24-03Equity from €4.8m to €2.7m
Key points
from the 2025 annual accountsResult
-€2.2m -€2.2m
From profit to loss in 2025, after a profit of €531,056 in 2024.
Investments
€546,484 1.8 × depreciation
Green is investment, beige is depreciation. Machinery stands 385.9% higher than in 2024.
Staff
4 employees on 31-12-2025
In 2025, 0 people joined and 3 left.
Filings
32 annual accounts 84 days
Latest accounts filed late: after the legal deadline.
Position in the sector
-€2.2m
Lower net result than 95% of companies in other professional activities. Sector median €12,609 · 816 companies.
Turnover not published (abbreviated or micro format)
Checked score
54
Fair
Financially stronger than 31% of micro companies in other professional activities (NACE 74)
Probability in this band: 1.5% to 4.2%
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59.
Bankruptcy probability within 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 5,429 companies (NACE 74, micro).
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.2%● unchanged vs 12-2024
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.3%▲ +0.1 percentage points vs 04-2025
06-2025: 0.2%▼ -0.1 percentage points vs 05-2025
07-2025: 0.3%▲ +0.1 percentage points vs 06-2025
08-2025: < 0.1%▼ -0.3 percentage points vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026lowest value
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.6%▲ +0.5 percentage points vs 09-2026highest value
11-2026: 0.6%● unchanged vs 10-2026highest value
Financial strengthAverage
Score breakdown
raises risk
Capped at 59: a net loss of at least half of total assets or of the equity at the start of the financial year
Loss of €2.2m (financial year 2025)
Last filed accounts filed 84 days late; 1 of the last 3 accounts late
lowers risk
Size: 6 FTE, total assets €4.3m
Equity €2.7m (61.7% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 74, micro). It does better than 63% of them on solvency, 41% on liquidity, 7% on profitability and 15% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 5,831 companies had the same profile as Anima Research has now. Each dot stands for 15 companies, two years later.
84.6%
were still trading
13.4%
stopped another way
1.7%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of Anima Research itself: 0.6% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 5,831 companies, not a prediction for Anima Research. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €140,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity is ample, with a current ratio of 1.86 (2.62 in 2024), above the usual 1.5. Short-term debt is 34.2% and cash 13.9% of total assets. 38.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 84 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-10-2026, 84 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
84 days late
2024
27 days early
2023
14 days late
2022
59 days late
2021
118 days early
2020
94 days late
2019
69 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 25 days after the deadline. In the sector (NACE 74), the median for financial year 2024 was 3 days before the deadline, and 38% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 15 August (4 of the last 5 accounts filed within 69 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
05-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
SC
SB CLINICAL CONSULTING BV
Director, since 29-04-2026
BV
BV VAN HAVERMAET BEDRIJFSREVISOREN
Auditor, Ira NICOLAIJ
- BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM 20%equity €80.9m (2025) · 2025 annual accounts of BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM
- EQUITY BNP PARIBAS FORTIS PRIVATE 20%annual accounts 2025
- RESEARCH ANIMA 0.67%annual accounts 2025
Shares in 1 company, ANIMA Clinical
Board & ownershipRecent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0452135608
Environmental permit granted
Bouwen of herbouwen, Het reliëf van de bodem aanmerkelijk wijzigen · Diepenbeek
Appointment: BV VAN HAVERMAET BEDRIJFSREVISOREN (statutory auditor)
Permanent representative: Ira NICOLAIJ · General meeting of 23-04-2025 · Gazette deed
Appointment: Linde Buntinx BV (day-to-day manager)
Permanent representative: Erik Buntinx · Board meeting of 04-12-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | Turnover | EBIT margin | Solvency | Staff |
|---|---|---|---|---|
| Anima Research Alken | - | - | 61.7% | 6 |
| CERTIPLANT Sint-Truiden | €1.1m | 18.8% | 52.5% | 3.8 |
| VP MEDIA SOLUTIONS Schaerbeek | €10.8m | 4.7% | 12.5% | 10.5 |
| ORTHOMEX Etterbeek | - | - | 41.8% | - |
| CROPLIFE EUROPE Brussels | €0.01m | - | 42.9% | 18.3 |
| Alma Terra Uccle | - | - | -32.1% | - |
| Eubelro Ham-sur-Heure-Nalinnes | - | - | 32.6% | - |
These companies have the same main activity as Anima Research: other professional, scientific and technical activities (NACE 74999). They are comparable in size and age: total assets between €1.3m and €11m, founded between 1983 and 2010.
Official details
Source: KBO- Status
- Active since 05-02-1994Normal situation
- Activity
- Other professional, scientific and technical activitiesNACE 74999and 3 others
- Joint committee
- 330.04Health institutions and services · annual accounts 2025
- Establishment units
- 2.184.363.5863570 Alken, since 05-02-1994
- 2.350.605.7503590 Diepenbeek, since 01-04-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 01-12-2025
Annual accounts 2025
- Total assets
- €4.3m▼ 40.4%
- Employeeson 31-12-2025
- 4▼ 42.9%
- Filing
- Filed on 23-10-2026
Insights on Anima Research
Anima Research files the abbreviated format. That format states no turnover. The gross margin fell from €104,189 in 2006 to -€1.3m in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Anima Research
- What is the company number of Anima Research?
- The company number of Anima Research is 0452.135.608. The VAT number is the same number with BE in front: BE 0452.135.608.
- Where is Anima Research based?
- The registered office is at Alkerstraat 28, 3570 Alken.Company details
- What does Anima Research do?
- According to the KBO register, the main activity is other professional, scientific and technical activities (NACE 74999).
- What is the legal form of Anima Research?
- Anima Research is a private limited company (BV).
- When was Anima Research founded?
- Anima Research was founded on 05-02-1994.
- Is Anima Research still active?
- Yes, Anima Research is an active enterprise in the KBO register.
- How many employees does Anima Research have?
- Anima Research had an average of 6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Anima Research fall under?
- In its 2025 annual accounts, Anima Research states joint committee 330.04 (Health institutions and services).
- What is the turnover of Anima Research?
- The annual accounts for financial year 2025 state no turnover. The abbreviated or micro format does not require it.
- Is Anima Research profitable?
- In financial year 2025, Anima Research made a loss of €2.2m.
- Where can I find the annual accounts of Anima Research?
- Anima Research filed 32 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Anima Research due?
- Anima Research must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.